Last reviewed 2026-05-30 · How we verify

ETEROBARB

Phase 2 active Small molecule ✓ Verified May 2026

ETEROBARB is a eterobarb drug. It is currently in Phase 2 development.

ETEROBARB works by interacting with a specific molecular target to produce a therapeutic effect.

ETEROBARB is a small molecule modality. It has multiple synonyms, including ETEROBARB, ETEROBARBE, ETEROBARBO, and EX 12-095.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETEROBARB
Drug class	eterobarb
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

In simple terms, ETEROBARB is thought to bind to a specific protein or receptor in the body, which helps to regulate a particular biological process. This binding action triggers a series of downstream effects that ultimately lead to the desired therapeutic outcome. However, the exact details of this process are not well understood due to the lack of available information.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ETEROBARB CI brief — competitive landscape report
ETEROBARB updates RSS · CI watch RSS

Frequently asked questions about ETEROBARB

What is ETEROBARB?

ETEROBARB is a eterobarb drug.

How does ETEROBARB work?

ETEROBARB works by interacting with a specific molecular target to produce a therapeutic effect.

What drug class is ETEROBARB in?

ETEROBARB belongs to the eterobarb class. See all eterobarb drugs at /class/eterobarb.

What development phase is ETEROBARB in?

ETEROBARB is in Phase 2.

Drug class: All eterobarb drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing